Lumbar Paravertebral Block vs Erector Spinae Plane Block in Elderly Patients Undergoing Lumbar Spine Surgery

NCT07607509 · tracked via the Priya Life Science Poland tracker

Sponsor

Poznan University of Medical Sciences

Phase

Not applicable

Started

2026-06-01

Last updated

2026-05-26

Condition(s) studied

Spine Disease

Investigational drug(s) / intervention(s)

Ropivacaine 0.2% Injectable Solution →Ropivacaine 0.2% Injectable Solution →

Ropivacaine 0.2% Injectable Solution: Ultrasound-guided bilateral interfascial plane block performed at the lumbar level for postoperative analgesia in patients undergoing lumbar spine surgery.

Ropivacaine 0.2% Injectable Solution: Ultrasound-guided bilateral paravertebral block at the lumbar level targeting spinal nerves for postoperative analgesia in patients undergoing lumbar spine surgery.

Study summary

This prospective, randomized controlled trial aims to compare the analgesic efficacy of lumbar paravertebral block (L-PVB) and lumbar erector spinae plane block (L-ESPB) in elderly patients undergoing lumbar spine surgery. Effective postoperative pain management in this population is essential due to increased susceptibility to opioid-related adverse effects.

Participants aged 65 years and older will be randomly assigned to receive either bilateral L-PVB or bilateral L-ESPB in addition to standardized general anesthesia. The primary objective is to evaluate differences in postoperative opioid consumption within the first 48 hours after surgery. Secondary outcomes include pain intensity, intraoperative opioid use, time to mobilization, length of hospital stay, and incidence of opioid-related adverse events.

Eligibility

Sex

ALL

Min age

65 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: * ge ≥65 years * Scheduled for elective lumbar spine surgery * American Society of Anesthesiologists (ASA) physical status I-III * Ability to assess pain using the Numeric Rating Scale (NRS) * Provision of written informed consent Exclusion Criteria: * Refusal to participate * Chronic opioid therapy * Coagulation disorders * Use of anticoagulant therapy contraindicating regional anesthesia * Infection at the planned needle insertion site * Allergy to ropivacaine or other study-related medications * Severe hepatic failure * Severe renal failure * Cognitive impairment preventing reliable pain assessment * Inability to cooperate with study procedures * Extensive reoperation or surgery of unusually large extent that may interfere with outcome assessment * Contraindications to general anesthesia or regional anesthesia

Primary outcome measure(s)

Total opioid consumption within 48 hours after surgery — 48 hours postoperatively
Total cumulative opioid consumption within the first 48 hours after surgery, converted to intravenous morphine equivalents.

Trial sites (1)

Facility	City	Region	Status
Poznan University of Medical Sciences	Poznan	Poland

More Poznan University of Medical Sciences trials in Poland

PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty Recruiting

Insulin Therapy and Lipoproteins' Profile in Type 1 Diabetes. Recruiting

The Hypotension Prediction Index Versus Standard Advanced Haemodynamic Monitoring in Patients Undergoing Major Aortic Surgery Recruiting

SII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty Recruiting

Demographic and Interpopulation Variations in Evaluation and Results of TAVI Enrolling by invitation

Other trials for the same condition

Comparison of Perineural Dexamethasone Versus Dexmedetomidine as Adjuvants to Erector Spinae Plane Block in Lumbar Spine Surgery: A Randomized, Double-blind, Controlled Trial Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07607509 on ClinicalTrials.gov ↗ ← All trials in Poland